My Chau T. Tran

Array ( [id] => 11602340 [patent_doc_number] => 20170119640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'Methods of Improving Glucose Tolerance, Hair Regrowth, and Bio-Availability' [patent_app_type] => utility [patent_app_number] => 14/924721 [patent_app_country] => US [patent_app_date] => 2015-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 731 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14924721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699329 [patent_doc_number] => 20160045476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'COMBINATION THERAPY WITH NITRATED LIPIDS AND INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM' [patent_app_type] => utility [patent_app_number] => 14/921880 [patent_app_country] => US [patent_app_date] => 2015-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5012 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14921880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864701 [patent_doc_number] => 20170231987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'LEVOSIMENDAN FOR USE IN THE TREATMENT OF MOTOR NEURON DISEASES (E.G. ALS)' [patent_app_type] => utility [patent_app_number] => 15/518949 [patent_app_country] => US [patent_app_date] => 2015-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2785 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10684281 [patent_doc_number] => 20160030427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'METHODS FOR REDUCING THE RISK OF AN ADVERSE TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION IN MULTIPLE SCLEROSIS PATIENTS' [patent_app_type] => utility [patent_app_number] => 14/880777 [patent_app_country] => US [patent_app_date] => 2015-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 1830 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14880777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14548685 [patent_doc_number] => 10342779 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Anhydrous liquid melatonin composition [patent_app_type] => utility [patent_app_number] => 15/514402 [patent_app_country] => US [patent_app_date] => 2015-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 23765 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10743224 [patent_doc_number] => 20160089375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-31 [patent_title] => 'TOPICAL OCULAR ANALGESIC AGENTS' [patent_app_type] => utility [patent_app_number] => 14/879439 [patent_app_country] => US [patent_app_date] => 2015-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3485 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14879439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11633919 [patent_doc_number] => 09655874 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-23 [patent_title] => 'Method for treating eczema' [patent_app_type] => utility [patent_app_number] => 14/868929 [patent_app_country] => US [patent_app_date] => 2015-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7807 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14868929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11697566 [patent_doc_number] => 09687463 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-27 [patent_title] => 'Method for treating eczema' [patent_app_type] => utility [patent_app_number] => 14/868959 [patent_app_country] => US [patent_app_date] => 2015-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7807 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14868959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10676479 [patent_doc_number] => 20160022624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'Method for Treating Eczema' [patent_app_type] => utility [patent_app_number] => 14/868897 [patent_app_country] => US [patent_app_date] => 2015-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7807 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14868897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10669546 [patent_doc_number] => 20160015692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'REGIMEN FOR SUPRESSING ORGAN REJECTION' [patent_app_type] => utility [patent_app_number] => 14/867773 [patent_app_country] => US [patent_app_date] => 2015-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11738 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14867773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12212380 [patent_doc_number] => 09909178 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-06 [patent_title] => 'Dalcetrapib for therapeutic use' [patent_app_type] => utility [patent_app_number] => 14/863148 [patent_app_country] => US [patent_app_date] => 2015-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 16822 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14863148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14609575 [patent_doc_number] => 10357465 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-23 [patent_title] => Eutectic formulations of cyclobenzaprine hydrochloride [patent_app_type] => utility [patent_app_number] => 15/511287 [patent_app_country] => US [patent_app_date] => 2015-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10802 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15511287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11789489 [patent_doc_number] => 09399026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-26 [patent_title] => 'Methods for alleviating statin myopathy' [patent_app_type] => utility [patent_app_number] => 14/853374 [patent_app_country] => US [patent_app_date] => 2015-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 9971 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14853374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10728364 [patent_doc_number] => 20160074513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'Long-Acting Semi-Solid Lipid Formulations' [patent_app_type] => utility [patent_app_number] => 14/853776 [patent_app_country] => US [patent_app_date] => 2015-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 11918 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14853776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12486840 [patent_doc_number] => 09993551 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => Combination therapies of EGFR inhibitors [patent_app_type] => utility [patent_app_number] => 15/510414 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27457 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15510414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699326 [patent_doc_number] => 20160045473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'Biological Basis Of Adult Wellness' [patent_app_type] => utility [patent_app_number] => 14/850417 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11176 [patent_no_of_claims] => 54 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10705403 [patent_doc_number] => 20160051550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/836827 [patent_app_country] => US [patent_app_date] => 2015-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 31563 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14836827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11640954 [patent_doc_number] => 09662302 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-30 [patent_title] => 'Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition' [patent_app_type] => utility [patent_app_number] => 14/823028 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 109 [patent_no_of_words] => 27965 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14823028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864706 [patent_doc_number] => 20170231986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor' [patent_app_type] => utility [patent_app_number] => 15/503217 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 192 [patent_figures_cnt] => 192 [patent_no_of_words] => 159227 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11850330 [patent_doc_number] => 20170224819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor' [patent_app_type] => utility [patent_app_number] => 15/503224 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 175 [patent_figures_cnt] => 175 [patent_no_of_words] => 163950 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503224 [rel_patent_id] =>[rel_patent_doc_number] =>)